Meditox vs Daewoong: 500bn KRW damages claim escalates in botulinum toxin trade‑secret case

Meditox and Daewoong Pharmaceutical have been involved in a long‑running lawsuit over alleged trade‑secret infringement related to botulinum toxin products. The amount Meditox is seeking in damages has increased to 500 billion KRW, drawing attention to the upcoming appeal proceedings. Meditox argues that the claim reflects Daewoong’s product sales, revenue, an expanded period for damage assessment, and higher compensation rules. Daewoong counters that the figure is based on Meditox’s arbitrary criteria and has not been recognized by the court. On the 4th, Daewoong submitted a request to the Seoul High Court to amend the claim’s purpose and legal basis in the ongoing appeal of the trade‑secret injunction case.